Diabetes drug may fight antipsychotic side effects
NCT ID NCT05669742
Summary
This study is testing whether adding the diabetes medication empagliflozin can help reduce weight gain and metabolic problems that often occur when people with schizophrenia take olanzapine. The trial involves 40 adults with schizophrenia who are already taking olanzapine. Participants will receive either empagliflozin or a placebo pill to see if the drug helps control these medication side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tanta Unuversity
RECRUITINGTanta, 34518, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.